Read news on mutant NSCLC with our app.
Read more in the app
Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases
Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC